TY PHAR.(002728)2025-01-24 09:55Financial Performance - The net profit attributable to shareholders for the reporting period is estimated to be between 20 million and 25 million yuan, representing a decline of 90.13% to 92.10% compared to the same period last year, which was 253.18 million yuan [3]. - The net profit after deducting non-recurring gains and losses is expected to be between 16.7 million and 21.7 million yuan, reflecting a decrease of 91.29% to 93.29% from the previous year's 249.01 million yuan [3]. - Basic earnings per share are projected to be between 0.04 yuan and 0.05 yuan, down from 0.55 yuan per share in the same period last year [3]. Marketing and Sales Strategy - The decline in performance is attributed to a marketing organizational transformation that led to reduced shipments of the core product, cough tablets, resulting in a significant drop in sales revenue [5]. - The company increased brand promotion efforts while reducing product shipments, leading to higher sales expenses during the reporting period [6]. - The marketing transformation aims to establish a self-operated organizational structure and direct business connections with terminal pharmacies, transitioning to new sales channels [7]. - The company is focusing on long-term development through marketing reforms and brand building, despite incurring short-term transformation costs [7]. Future Reporting - The specific financial data will be detailed in the 2024 annual report, as the current figures are preliminary estimates [7].